EXEL Exelixis Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: EXEL

Price (delayed)

$21.85

Market cap

$6.96B

P/E Ratio

42.84

Dividend/share

N/A

EPS

$0.51

Enterprise value

$6.69B

Founded in 1994, Exelixis, Inc. is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work ...

Highlights
The gross profit has grown by 10% YoY and by 2.9% from the previous quarter
The revenue has grown by 10% YoY and by 3% from the previous quarter
The company's EPS fell by 40% YoY but it rose by 6% QoQ
The company's net income fell by 40% YoY but it rose by 7% QoQ
The P/E is 40% above the last 4 quarters average of 30.6 and 40% above the 5-year quarterly average of 30.7
EXEL's quick ratio is down by 24% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.exelixis.com
Peers: MRK BMY AMGN CRIS

Key stats

What are the main financial stats of EXEL
Market
Shares outstanding
318.38M
Market cap
$6.96B
Enterprise value
$6.69B
Valuations
Price to earnings (P/E)
42.84
Price to book (P/B)
2.81
Price to sales (P/S)
4.13
EV/EBIT
31.95
EV/EBITDA
25.75
EV/Sales
3.9
Earnings
Revenue
$1.71B
EBIT
$209.28M
EBITDA
$259.64M
Free cash flow
$361.43M
Per share
EPS
$0.51
Free cash flow per share
$1.11
Book value per share
$7.76
Revenue per share
$5.29
TBVPS
$9.5
Balance sheet
Total assets
$3.14B
Total liabilities
$614.53M
Debt
$194.69M
Equity
$2.53B
Working capital
$1.25B
Liquidity
Debt to equity
0.08
Current ratio
4.68
Quick ratio
4.42
Net debt/EBITDA
-1.04
Margins
EBITDA margin
15.1%
Gross margin
96.3%
Net margin
9.6%
Operating margin
8.2%
Efficiency
Return on assets
5.3%
Return on equity
6.5%
Return on invested capital
9%
Return on capital employed
7.5%
Return on sales
12.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EXEL stock price

How has the Exelixis stock price performed over time
Intraday
-2.41%
1 week
1.72%
1 month
-2.46%
1 year
37.94%
YTD
36.22%
QTD
14.34%

Financial performance

How have Exelixis's revenue and profit performed over time
Revenue
$1.71B
Gross profit
$1.65B
Operating income
$141.22M
Net income
$164.24M
Gross margin
96.3%
Net margin
9.6%
EXEL's operating margin has dropped by 62% year-on-year and by 7% since the previous quarter
Exelixis's operating income has shrunk by 58% YoY and by 4% QoQ
The net margin has decreased by 45% YoY but it has increased by 4.3% from the previous quarter
The company's net income fell by 40% YoY but it rose by 7% QoQ

Growth

What is Exelixis's growth rate over time

Valuation

What is Exelixis stock price valuation
EXEL P/E details
P/E
42.84
P/B
2.81
P/S
4.13
EV/EBIT
31.95
EV/EBITDA
25.75
EV/Sales
3.9
The P/E is 40% above the last 4 quarters average of 30.6 and 40% above the 5-year quarterly average of 30.7
The company's EPS fell by 40% YoY but it rose by 6% QoQ
EXEL's P/B is 22% above its last 4 quarters average of 2.3 but 17% below its 5-year quarterly average of 3.4
The company's equity rose by 6% YoY
EXEL's price to sales (P/S) is 26% lower than its 5-year quarterly average of 5.6 but 21% higher than its last 4 quarters average of 3.4
The revenue has grown by 10% YoY and by 3% from the previous quarter

Efficiency

How efficient is Exelixis business performance
The ROIC has plunged by 55% YoY
The ROA has contracted by 49% YoY but it has grown by 3.9% from the previous quarter
The company's return on equity fell by 46% YoY but it rose by 4.8% QoQ
The company's return on sales fell by 45% YoY but it rose by 2.5% QoQ

Dividends

What is EXEL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EXEL.

Financial health

How did Exelixis financials performed over time
EXEL's total liabilities is up by 25% year-on-year and by 4.5% since the previous quarter
EXEL's quick ratio is down by 24% year-on-year and by 6% since the previous quarter
The debt is 92% less than the equity
The debt has increased by 21% YoY and by 4.1% from the previous quarter
The company's debt to equity rose by 14% QoQ and by 14% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.